Cytogenetic Effects of LSD 25 Therapy in Man
JAMA December 2, 1968 David A. Hungerford 40 citations
Chromosomes from leukocytes of patients receiving intravenous lysergic acid diethylamide (LSD 25) were examined for aberrations. Before therapy, aberration frequencies in three of four patients matched those of control subjects. After each of three doses (usually 200 μg), some increase in aberration frequency and new types of aberrations appeared. However, follow-up samples taken one to six months after the final dose showed a return to control levels. The authors conclude that continued experimental therapy is not strongly contraindicated, but these results do not minimize potential cytogenetic hazards suggested by studies of drug abuse.